A detailed history of State Of Wisconsin Investment Board transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 30,954 shares of AKRO stock, worth $919,643. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,954
Previous 32,781 5.57%
Holding current value
$919,643
Previous $828,000 12.32%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$18.31 - $24.62 $33,452 - $44,980
-1,827 Reduced 5.57%
30,954 $726,000
Q1 2024

May 14, 2024

SELL
$17.76 - $31.18 $588,779 - $1.03 Million
-33,152 Reduced 50.28%
32,781 $828,000
Q4 2023

Feb 12, 2024

BUY
$11.38 - $50.33 $163,268 - $722,084
14,347 Added 27.81%
65,933 $1.54 Million
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $424,257 - $538,175
10,300 Added 24.95%
51,586 $2.61 Million
Q2 2023

Aug 14, 2023

BUY
$36.89 - $56.88 $411,950 - $635,178
11,167 Added 37.08%
41,286 $1.93 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $50.24 $54,078 - $72,898
1,451 Added 5.06%
30,119 $1.15 Million
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $337,309 - $552,767
10,087 Added 54.29%
28,668 $1.57 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $4,212 - $14,130
415 Added 2.28%
18,581 $633,000
Q2 2022

Aug 15, 2022

SELL
$8.0 - $15.01 $121,072 - $227,161
-15,134 Reduced 45.45%
18,166 $172,000
Q2 2021

Aug 12, 2021

BUY
$24.81 - $32.35 $374,631 - $488,485
15,100 Added 82.97%
33,300 $826,000
Q1 2021

May 17, 2021

SELL
$24.04 - $34.19 $19,232 - $27,352
-800 Reduced 4.21%
18,200 $528,000
Q4 2020

Feb 03, 2021

BUY
$25.12 - $29.89 $153,232 - $182,329
6,100 Added 47.29%
19,000 $490,000
Q1 2020

May 06, 2020

BUY
$12.8 - $27.05 $165,120 - $348,945
12,900 New
12,900 $273,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.38B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.